Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Taking the brake off. Immunotherapy induced dysfunction with Immune Checkpoint Inhibitors

World Congress on Immuno Oncology & Clinical Pharmacy
April 18-19, 2019 | Paris, France

Yasar Ahmed, Sam Lee and Ala Yousif

University Hospital Waterford, Ireland. Sligo University Hospital, Ireland. Galway University Hospital , Ireland

Scientific Tracks Abstracts: Arch Cancer Res

Abstract:

Background: Targeting the immune checkpoints cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) and programmed death 1 (PD-1) with inhibitory antibodies has demonstrated effective and durable antitumor activity in subgroups of patients with cancer. Thyroid-Related Adverse Events ( TRAEs) have emerged as one of the most common immune-related adverse events of Immune checkpoint blockade therapy with a reported incidence range of 2%-15% depending upon the Immune checkpoint blockade used. The aim of this study is to describe the incidence of TRAEs retrospectively in patients who received Immune checkpoint blockade therapy.

Methods: A total of 285 patients were reviewed (178 male, 107 female; 16-94 years of age), of whom 218 had no baseline TRAEs, 61 had baseline TRAEs, and 6 had a history of thyroidectomy (excluded). At least one dose of ipilimumab and/or nivolumab or pembrolizumab was administered. Post- Immune checkpoint blockade therapy TRAEs were classified according to standard definitions of thyroid conditions when possible.

Results: A total of 35% (76/218) patients had new-onset TRAEs on ICI therapy. Of note, 70.5% (43/61) had baseline TRAEs that were exacerbated by Immune checkpoint blockade therapy. The median times to new-onset or exacerbated baseline TRAEs were 46 and 33 days, respectively. Of note, 64.5% (20/31) of patients on both ipilimumab and nivolumab had new-onset TRAEs, compared with 31.3% (15/48) on ipilimumab, 31.5% (28/89) on nivolumab, and 26% (13/50) on pembrolizumab.

Conclusion: The incidence of TRAEs with ICI therapy was higher than previously reported. Patients with baseline TRAEs and/or who were receiving ipilimumab and nivolumab combination therapy had a higher incidence of TRAEs than patients receiving single-agent Immune checkpoint blockade therapy. We recommend more frequent evaluation of thyroid function in the first 8 weeks, especially in patients with baseline TRAEs.

Biography :

Yasar Ahmed is a doctor at University Hospital Waterford, Ireland. His interest includes Cancer Biomarkers, Clinical Immunology, Anti-Cancer Drugs, Biochemistry Of Cancer and Immunogenomics. He has published more than 20 papers in reputed journals.

E-mail: [email protected]